SAB-176 Emerging Drug Insight and Market Forecast - 2032

This “SAB-176 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about SAB-176 for seasonal influenza in the seven major markets. A detailed picture of the SAB-176 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SAB-176 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAB-176 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary

SAB-176 is a quadrivalent broadly neutralizing fully human polyclonal antibody therapeutic candidate developed by SAb Biotherapeutics that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company's proprietary technology, the DiversitAb platform, is designed to bind to Type A and B influenza viruses. It may also be modified to address annual strain changes when needed.

Preclinical data suggest that SAB-176 offers potentially broad protection against diverse influenza strains. A highly potent, polyclonal antibody therapy for severe seasonal influenza could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune-compromised. Like vaccines, it can also be modified to address annual strain changes when needed.

Recently the company announced the developmental plan for SAB-176. The company plans to begin a Phase IIb study by the second half of 2023. Moreover, the company anticipates that it might start the Phase III trial by 2025 and expects Phase IIb topline results of the ongoing trial by 2024.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SAB-176 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on SAB-176 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAB-176 research and development activities in seasonal influenza across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SAB-176.
• The report contains forecasted sales of SAB-176 for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for SAB-176 in seasonal influenza.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAB-176 Analytical Perspective

In-depth SAB-176 Market Assessment

This report provides a detailed market assessment of SAB-176 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

SAB-176 Clinical Assessment

The report provides the clinical trials information of SAB-176 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAB-176 dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to SAB-176 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAB-176 in seasonal influenza.
• This in-depth analysis of the forecasted sales data of SAB-176 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAB-176 in seasonal influenza.

Key Questions

• What is the product type, route of administration and mechanism of action of SAB-176?
• What is the clinical trial status of the study related to SAB-176 in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAB-176 development?
• What are the key designations that have been granted to SAB-176 for seasonal influenza?
• What is the forecasted market scenario of SAB-176 for seasonal influenza?
• What are the forecasted sales of SAB-176 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to SAB-176 for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

This product will be delivered within 2 business days.